Protected cytoskeletal‑related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer

Segarra,Daniel   T.; Yavorski,John  M.; Blanck,George

doi:10.3892/br.2017.940

Protected cytoskeletal‑related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer

Authors:
- Daniel T. Segarra
- John M. Yavorski
- George Blanck
View Affiliations

Affiliations: Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
Published online on: July 6, 2017 https://doi.org/10.3892/br.2017.940
Pages: 163-168

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Initial reports of the role of the cytoskeleton in cancer indicated that tumor cells with a more disorganized cytoskeleton were more tumorigenic. These reports were based on stains for the F‑actin cytoskeleton, for example, using phalloidin or anti‑F‑actin antibody reagents, and gave a basic impression of F‑actin‑based cytoskeletal integrity. Later developments emphasized the significance of the cytoskeletal elements in cell migration, presumably associated with either basement membrane invasion or metastasis, or both, with several specific proteins implicated in the formation of cell invadopodia. With the advent of genomics approaches, it has become clear that cytoskeletal related proteins are indeed common targets of mutagenesis in cancer and commonly rank among the most mutated proteins in cancers, presumably due to large coding region sizes and the significant stochastic component to human mutagenesis. This cytoskeletal genomics result is consistent with the loss of cytoskeleton integrity as a hallmark of tumor development, but raises the question of whether such mutational sensitivity relates to the migration and invadopodia aspects of tumor progression. In the present study, the authors report that it is possible to identify a set of cytoskeletal related proteins protected from mutation, in comparison to the commonly mutated cytoskeleton related proteins in certain, but not all cancer, datasets.

View Figures

View References

1	Vogel A, Risser R and Pollack R: Isolation and characterization of revertant cell lines. 3. Isolation of density-revertants of SV40-transformed 3T3 cells using colchicine. J Cell Physiol. 82:181–188. 1973. View Article : Google Scholar : PubMed/NCBI
2	Pollack RE, Green H and Todaro GJ: Growth control in cultured cells: Selection of sublines with increased sensitivity to contact inhibition and decreased tumor-producing ability. Proc Natl Acad Sci USA. 60:126–133. 1968. View Article : Google Scholar : PubMed/NCBI
3	Verderame M, Alcorta D, Egnor M, Smith K and Pollack R: Cytoskeletal F-actin patterns quantitated with fluorescein isothiocyanate-phalloidin in normal and transformed cells. Proc Natl Acad Sci USA. 77:6624–6628. 1980. View Article : Google Scholar : PubMed/NCBI
4	Kopelovich L, Conlon S and Pollack R: Defective organization of actin in cultured skin fibroblasts from patients with inherited adenocarcinoma. Proc Natl Acad Sci U S A. 74:3019–3022. 1977. View Article : Google Scholar : PubMed/NCBI
5	Shin SI, Freedman VH, Risser R and Pollack R: Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA. 72:4435–4439. 1975. View Article : Google Scholar : PubMed/NCBI
6	Steinberg BM, Rifkin D, Shin S, Boone C and Pollack R: Tumorigenicity of revertant from an SV40-transformed line. J Supramol Struct. 11:539–546. 1979. View Article : Google Scholar : PubMed/NCBI
7	Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, Lee JC, Henze J, Fletcher BS, Gu Z, et al: Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 46:601–606. 2014. View Article : Google Scholar : PubMed/NCBI
8	Fernandez K, Serinagaoglu Y, Hammond S, Martin LT and Martin PT: Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. Am J Pathol. 176:416–434. 2010. View Article : Google Scholar : PubMed/NCBI
9	Parry ML, Ramsamooj M and Blanck G: Big genes are big mutagen targets: A connection to cancerous, spherical cells? Cancer Lett. 356(2 Pt B): 1–482. 2015.
10	Parry ML and Blanck G: Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens? Hum Vaccin Immunother. 12:120–123. 2016. View Article : Google Scholar : PubMed/NCBI
11	Fawcett TJ, Parry ML and Blanck G: A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates. Cancer Genomics Proteomics. 12:283–290. 2015.PubMed/NCBI
12	Zachary JM, Cleveland G, Kwock L, Lawrence T, Weissman RM, Nabell L, Fried FA, Staab EV, Risinger MA and Lin S: Actin filament organization of the Dunning R3327 rat prostatic adenocarcinoma system: Correlation with metastatic potential. Cancer Res. 46:926–932. 1986.PubMed/NCBI
13	Xu W, Mezencev R, Kim B, Wang L, McDonald J and Sulchek T: Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. PLoS One. 7:e466092012. View Article : Google Scholar : PubMed/NCBI
14	Bear JE and Haugh JM: Directed migration of mesenchymal cells: Where signaling and the cytoskeleton meet. Curr Opin Cell Biol. 30:74–82. 2014. View Article : Google Scholar : PubMed/NCBI
15	Verschueren H, Van der Taelen I, Dewit J, De Braekeleer J and De Baetselier P: Metastatic competence of BW5147 T-lymphoma cell lines is correlated with in vitro invasiveness, motility and F-actin content. J Leukoc Biol. 55:552–556. 1994.PubMed/NCBI
16	Nürnberg A, Kitzing T and Grosse R: Nucleating actin for invasion. Nat Rev Cancer. 11:177–187. 2011. View Article : Google Scholar : PubMed/NCBI
17	Kim TY, Vigil D, Der CJ and Juliano RL: Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev. 28:77–83. 2009. View Article : Google Scholar : PubMed/NCBI
18	Carisey A, Tsang R, Greiner AM, Nijenhuis N, Heath N, Nazgiewicz A, Kemkemer R, Derby B, Spatz J and Ballestrem C: Vinculin regulates the recruitment and release of core focal adhesion proteins in a force-dependent manner. Curr Biol. 23:271–281. 2013. View Article : Google Scholar : PubMed/NCBI
19	Thakur RK, Yadav VK, Kumar A, Singh A, Pal K, Hoeppner L, Saha D, Purohit G, Basundra R, Kar A, et al: Non-metastatic 2 (NME2)-mediated suppression of lung cancer metastasis involves transcriptional regulation of key cell adhesion factor vinculin. Nucleic Acids Res. 42:11589–11600. 2014. View Article : Google Scholar : PubMed/NCBI
20	Gilardi M, Bersini S, Calleja AB, Kamm RD, Vanoni M and Moretti M: PO-12 - The key role of talin-1 in cancer cell extravasation dissected through human vascularized 3D microfluidic model. Thromb Res. 140 Suppl 1:S180–S181. 2016. View Article : Google Scholar : PubMed/NCBI
21	Liu M, Oberg K and Zhou Y: Expression and function of vinculin in neuroendocrine tumors. Tumour Biol. 28:196–204. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zhang W, Mao YQ, Wang H, Yin WJ, Zhu SX and Wang WC: MiR-124 suppresses cell motility and adhesion by targeting talin 1 in prostate cancer cells. Cancer Cell Int. 15:492015. View Article : Google Scholar : PubMed/NCBI
23	Samy MD, Tong WL, Yavorski JM, Sexton WJ and Blanck G: T cell receptor gene recombinations in human tumor specimen exome files: Detection of T cell receptor-β VDJ recombinations associates with a favorable oncologic outcome for bladder cancer. Cancer Immunol Immunother. 66:403–410. 2017. View Article : Google Scholar : PubMed/NCBI